Labiana Health (XMAD:LAB) Unearned Premiums

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:LAB Labiana Health SA XMAD:LAB
57 GF Score
Price €6.65
GF Value €3.59
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Labiana Health Unearned Premiums?

Unearned Premiums only applies to insurance companies.

XMAD:LAB
57GF Score
Labiana Health SA XMAD:LAB
Unearned Premiums is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Labiana Health (XMAD:LAB) Overvalued in 2026?

Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued. The current stock price of €6.65 is trading 85.2% above its estimated GF Value™ of €3.59. GuruFocus considers Labiana Health to be Significantly Overvalued.

Key valuation signals for XMAD:LAB:

  • Unearned Premiums:
  • GF Value™: €3.59 vs. price of €6.65 (85.2% above fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the XMAD:LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Labiana Health Business Description

Other Exchanges 8RK:Germany
Address Avenida Europa, 34 1st D, Pozuelo de Alarcon, Madrid, ESP, 28023
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
57GF Score

Get the complete analysis for XMAD:LAB

Unearned Premiums is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.65
Price
€3.59
GF Value